A Phase 1, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Local Muscle Injections of ACE-083 in Healthy Postmenopausal Women
Phase of Trial: Phase I
Latest Information Update: 08 Jul 2016
At a glance
- Drugs ACE 083 (Primary)
- Indications Muscular dystrophies
- Focus Adverse reactions; First in man
- Sponsors Acceleron Pharma
- 08 Jul 2016 According to an Acceleron Pharma media release, results from this trial were presented at the 14th International Congress on Neuromuscular Disease.
- 08 Jul 2016 Results published in the Acceleron Pharma media release.
- 29 Jun 2016 According to an Acceleron Pharma media release, results from this trial will be presented at the 14th International Congress on Neuromuscular Disease (ICNMD 2016).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History